T2 Biosystems (TTOO) Stock Forecast, Price Target & Predictions
TTOO Stock Forecast
T2 Biosystems stock forecast is as follows: an average price target of $5.00 (represents a 97.63% upside from TTOO’s last price of $2.53) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
TTOO Price Target
The average price target for T2 Biosystems (TTOO) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 97.63% upside from TTOO's last price of $2.53.
TTOO Analyst Ratings
According to 1 Wall Street analysts, T2 Biosystems's rating consensus is 'Hold'. The analyst rating breakdown for TTOO stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
T2 Biosystems Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Kyle Mikson | Canaccord Genuity | $5.00 | $4.74 | 5.49% | 97.63% |
The latest T2 Biosystems stock forecast, released on Jul 30, 2024 by Kyle Mikson from Canaccord Genuity, set a price target of $5.00, which represents a 5.49% increase from the stock price at the time of the forecast ($4.74), and a 97.63% increase from TTOO last price ($2.53).
T2 Biosystems Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $2.53 | $2.53 | $2.53 |
| Upside/Downside | -100.00% | 97.63% | 97.63% |
In the current month, the average price target of T2 Biosystems stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to T2 Biosystems's last price of $2.53. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 30, 2024 | Canaccord Genuity | Hold | Hold | Hold |
T2 Biosystems's last stock rating was published by Canaccord Genuity on Jul 30, 2024. The company gave TTOO a "Hold" rating, the same as its previous rate.
T2 Biosystems Financial Forecast
T2 Biosystems Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $1.96M | $2.08M | $5.48M | $3.68M | - | $7.23M | $6.98M | $7.43M | $6.69M | $6.96M | $7.79M | $5.25M | $2.55M | $2.54M | $3.07M | $1.68M | $1.80M | $1.78M | $2.47M | $3.93M |
| Avg Forecast | $7.28M | $6.16M | $5.24M | $4.44M | $3.69M | $2.85M | $2.10M | $1.60M | $2.40M | $1.50M | $2.17M | $2.33M | $5.39M | $4.72M | $6.14M | $6.65M | $6.19M | $5.79M | $6.14M | $6.43M | $7.96M | $5.14M | $2.36M | $2.63M | $3.39M | $2.04M | $2.00M | $1.41M | $3.26M | $3.93M |
| High Forecast | $7.28M | $6.16M | $5.24M | $4.44M | $3.69M | $2.85M | $2.10M | $1.60M | $2.61M | $1.50M | $2.17M | $2.33M | $5.39M | $4.72M | $6.14M | $6.65M | $6.19M | $5.79M | $6.14M | $6.43M | $7.96M | $5.14M | $2.36M | $2.63M | $3.39M | $2.04M | $2.00M | $1.41M | $3.91M | $4.72M |
| Low Forecast | $7.28M | $6.16M | $5.24M | $4.44M | $3.69M | $2.85M | $2.10M | $1.60M | $2.19M | $1.50M | $2.17M | $2.33M | $5.39M | $4.72M | $6.14M | $6.65M | $6.19M | $5.79M | $6.14M | $6.43M | $7.96M | $5.14M | $2.36M | $2.63M | $3.39M | $2.04M | $2.00M | $1.41M | $2.60M | $3.14M |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.89% | 1.02% | 0.78% | - | 1.09% | 1.13% | 1.28% | 1.09% | 1.08% | 0.98% | 1.02% | 1.08% | 0.97% | 0.91% | 0.82% | 0.90% | 1.27% | 0.76% | 1.00% |
T2 Biosystems's average Quarter revenue forecast for Sep 23 based on 0 analysts is $1.50M, with a low forecast of $1.50M, and a high forecast of $1.50M. TTOO's average Quarter revenue forecast represents a -23.63% decrease compared to the company's last Quarter revenue of $1.96M (Jun 23).
T2 Biosystems EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-13.05M | $-14.11M | $-9.74M | $-15.23M | - | $-14.27M | $-9.63M | $-11.46M | $-10.19M | $-8.84M | $-9.07M | $-9.04M | $-8.83M | $-12.63M | $-11.47M | $-11.40M | $-12.68M | $-12.47M | $-8.29M | $-10.22M |
| Avg Forecast | $-7.28M | $-6.16M | $-5.24M | $-4.44M | $-3.69M | $-2.85M | $-2.10M | $-7.22M | $-2.40M | $-1.50M | $-2.17M | $-7.72M | $-5.39M | $-7.90M | $-6.14M | $-8.26M | $-9.93M | $-8.45M | $-10.19M | $-8.84M | $-7.96M | $-9.04M | $-12.37M | $-13.18M | $-10.62M | $-12.10M | $-11.49M | $-10.80M | $-10.30M | $-10.22M |
| High Forecast | $-7.28M | $-6.16M | $-5.24M | $-4.44M | $-3.69M | $-2.85M | $-2.10M | $-5.78M | $-2.19M | $-1.50M | $-2.17M | $-6.18M | $-5.39M | $-6.32M | $-6.14M | $-6.61M | $-7.94M | $-6.76M | $-8.15M | $-7.07M | $-7.96M | $-7.23M | $-9.89M | $-10.55M | $-8.49M | $-9.68M | $-9.19M | $-8.64M | $-8.24M | $-8.18M |
| Low Forecast | $-7.28M | $-6.16M | $-5.24M | $-4.44M | $-3.69M | $-2.85M | $-2.10M | $-8.67M | $-2.61M | $-1.50M | $-2.17M | $-9.27M | $-5.39M | $-9.49M | $-6.14M | $-9.91M | $-11.91M | $-10.15M | $-12.23M | $-10.60M | $-7.96M | $-10.85M | $-14.84M | $-15.82M | $-12.74M | $-14.52M | $-13.79M | $-12.96M | $-12.36M | $-12.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 6.01% | 1.83% | 1.81% | 1.93% | - | 1.73% | 0.97% | 1.36% | 1.00% | 1.00% | 1.14% | 1.00% | 0.71% | 0.96% | 1.08% | 0.94% | 1.10% | 1.15% | 0.80% | 1.00% |
undefined analysts predict TTOO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than T2 Biosystems's previous annual EBITDA (undefined) of $NaN.
T2 Biosystems Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-6.35M | $-20.04M | $-11.45M | $-18.95M | - | $-18.13M | $-14.10M | $-13.96M | $-12.47M | $-10.66M | $-9.91M | $-11.26M | $-10.69M | $-14.95M | $-14.04M | $-14.17M | $-15.65M | $-15.15M | $-10.77M | $-12.32M |
| Avg Forecast | $-3.24M | $-3.95M | $-4.65M | $-5.64M | $-6.91M | $-9.02M | $-13.67M | $-8.71M | $-31.29M | $-327.43M | $-375.88M | $-9.32M | $-3.28B | $-9.84M | $-2.29B | $-9.97M | $-12.16M | $-10.52M | $-12.47M | $-10.66M | $-1.38B | $-11.26M | $-14.96M | $-15.60M | $-13.00M | $-15.03M | $-14.18M | $-13.13M | $-13.38M | $-12.32M |
| High Forecast | $-3.24M | $-3.95M | $-4.65M | $-5.64M | $-6.91M | $-9.02M | $-13.67M | $-6.97M | $-31.29M | $-327.43M | $-375.88M | $-7.46M | $-3.28B | $-7.87M | $-2.29B | $-7.97M | $-9.72M | $-8.42M | $-9.98M | $-8.53M | $-1.38B | $-9.00M | $-11.97M | $-12.48M | $-10.40M | $-12.02M | $-11.34M | $-10.50M | $-10.70M | $-9.86M |
| Low Forecast | $-3.24M | $-3.95M | $-4.65M | $-5.64M | $-6.91M | $-9.02M | $-13.67M | $-10.46M | $-31.29M | $-327.43M | $-375.88M | $-11.18M | $-3.28B | $-11.81M | $-2.29B | $-11.96M | $-14.59M | $-12.63M | $-14.97M | $-12.79M | $-1.38B | $-13.51M | $-17.95M | $-18.72M | $-15.60M | $-18.04M | $-17.02M | $-15.75M | $-16.05M | $-14.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.02% | 2.15% | 0.00% | 1.93% | - | 1.82% | 1.16% | 1.33% | 1.00% | 1.00% | 0.01% | 1.00% | 0.71% | 0.96% | 1.08% | 0.94% | 1.10% | 1.15% | 0.80% | 1.00% |
T2 Biosystems's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TTOO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
T2 Biosystems SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $6.30M | $7.30M | $6.67M | $7.02M | - | $9.23M | $6.54M | $8.54M | $7.24M | $6.20M | $4.60M | $5.08M | $5.11M | $6.50M | $7.55M | $5.98M | $6.72M | $7.05M | $5.87M | $7.61M |
| Avg Forecast | $15.00M | $12.70M | $10.79M | $9.14M | $7.60M | $5.87M | $4.32M | $3.30M | $4.94M | $3.09M | $4.47M | $4.80M | $11.11M | $4.44M | $12.64M | $5.80M | $12.74M | $4.75M | $12.65M | $6.20M | $16.39M | $5.08M | $4.86M | $5.43M | $6.98M | $4.19M | $4.11M | $2.90M | $6.70M | $8.10M |
| High Forecast | $15.00M | $12.70M | $10.79M | $9.14M | $7.60M | $5.87M | $4.32M | $3.30M | $5.37M | $3.09M | $4.47M | $4.80M | $11.11M | $5.33M | $12.64M | $6.96M | $12.74M | $5.70M | $12.65M | $7.44M | $16.39M | $6.10M | $4.86M | $5.43M | $6.98M | $4.19M | $4.11M | $2.90M | $8.04M | $9.71M |
| Low Forecast | $15.00M | $12.70M | $10.79M | $9.14M | $7.60M | $5.87M | $4.32M | $3.30M | $4.51M | $3.09M | $4.47M | $4.80M | $11.11M | $3.55M | $12.64M | $4.64M | $12.74M | $3.80M | $12.65M | $4.96M | $16.39M | $4.07M | $4.86M | $5.43M | $6.98M | $4.19M | $4.11M | $2.90M | $5.36M | $6.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.41% | 1.52% | 0.60% | 1.58% | - | 1.59% | 0.51% | 1.80% | 0.57% | 1.00% | 0.28% | 1.00% | 1.05% | 1.20% | 1.08% | 1.43% | 1.63% | 2.43% | 0.88% | 0.94% |
T2 Biosystems's average Quarter SG&A projection for Sep 23 is $3.09M, based on 0 Wall Street analysts, with a range of $3.09M to $3.09M. The forecast indicates a -50.94% fall compared to TTOO last annual SG&A of $6.30M (Jun 23).
T2 Biosystems EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-7.84 | $-1.47 | $-2.25K | $-3.15 | - | $-5.34 | $-4.24 | $-4.21 | $-4.03 | $-3.60 | $-3.34 | $-3.81 | $-4.44 | $-10.89 | $-10.23 | $-15.60 | $-17.61 | $-17.10 | $-12.30 | $-16.10 |
| Avg Forecast | $-0.23 | $-0.28 | $-0.33 | $-0.40 | $-0.49 | $-0.64 | $-0.97 | $-1.86 | $-2.22 | $-23.23 | $-26.67 | $-120.22 | $-233.00 | $-211.32 | $-450.00 | $-372.88 | $-450.88 | $-433.33 | $-386.54 | $-370.00 | $-338.90 | $-390.00 | $-750.00 | $-1.18K | $-1.36K | $-1.57K | $-1.61K | $-1.51K | $-0.41 | $-0.32 |
| High Forecast | $-0.23 | $-0.28 | $-0.33 | $-0.40 | $-0.49 | $-0.64 | $-0.97 | $-1.86 | $-2.22 | $-23.23 | $-26.67 | $-120.22 | $-233.00 | $-211.32 | $-450.00 | $-372.88 | $-450.88 | $-433.33 | $-386.54 | $-370.00 | $-338.90 | $-390.00 | $-750.00 | $-1.18K | $-1.36K | $-1.57K | $-1.61K | $-1.51K | $-0.33 | $-0.26 |
| Low Forecast | $-0.23 | $-0.28 | $-0.33 | $-0.40 | $-0.49 | $-0.64 | $-0.97 | $-1.86 | $-2.22 | $-23.23 | $-26.67 | $-120.22 | $-233.00 | $-211.32 | $-450.00 | $-372.88 | $-450.88 | $-433.33 | $-386.54 | $-370.00 | $-338.90 | $-390.00 | $-750.00 | $-1.18K | $-1.36K | $-1.57K | $-1.61K | $-1.51K | $-0.49 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.29% | 0.01% | 9.64% | 0.01% | - | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 30.00% | 50.33% |
According to undefined Wall Street analysts, T2 Biosystems's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TTOO previous annual EPS of $NaN (undefined).
T2 Biosystems Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TTOO | T2 Biosystems | $2.53 | $5.00 | 97.63% | Hold |
| ILMN | Illumina | $129.18 | $200.82 | 55.46% | Buy |
| DHR | Danaher | $274.25 | $313.59 | 14.34% | Buy |
| TMO | Thermo Fisher Scientific | $611.17 | $646.05 | 5.71% | Buy |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| IDXX | IDEXX Laboratories | $500.55 | $479.75 | -4.16% | Buy |
| HTGM | HTG Molecular Diagnostics | $0.48 | $0.17 | -64.58% | Buy |
TTOO Forecast FAQ
Is T2 Biosystems a good buy?
No, according to 1 Wall Street analysts, T2 Biosystems (TTOO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of TTOO's total ratings.
What is TTOO's price target?
T2 Biosystems (TTOO) average price target is $5 with a range of $5 to $5, implying a 97.63% from its last price of $2.53. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will T2 Biosystems stock go up soon?
According to Wall Street analysts' prediction for TTOO stock, the company can go up by 97.63% (from the last price of $2.53 to the average price target of $5), up by 97.63% based on the highest stock price target, and up by 97.63% based on the lowest stock price target.
Can T2 Biosystems stock reach $4?
TTOO's average twelve months analyst stock price target of $5 supports the claim that T2 Biosystems can reach $4 in the near future.
What are T2 Biosystems's analysts' financial forecasts?
T2 Biosystems's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.24M (high $10.24M, low $10.24M), average EBITDA is $-15.861M (high $-14.417M, low $-17.306M), average net income is $-38.314M (high $-36.571M, low $-40.056M), average SG&A $21.09M (high $21.09M, low $21.09M), and average EPS is $-3.96 (high $-3.96, low $-3.96). TTOO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.13M (high $23.13M, low $23.13M), average EBITDA is $-23.125M (high $-23.125M, low $-23.125M), average net income is $-17.478M (high $-17.478M, low $-17.478M), average SG&A $47.62M (high $47.62M, low $47.62M), and average EPS is $-1.24 (high $-1.24, low $-1.24).
Did the TTOO's actual financial results beat the analysts' financial forecasts?
Based on T2 Biosystems's last annual report (Dec 2022), the company's revenue was $22.3M, which missed the average analysts forecast of $22.91M by -2.62%. Apple's EBITDA was $-55.471M, beating the average prediction of $-27.697M by 100.28%. The company's net income was $-63.37M, missing the average estimation of $-5.597B by -98.87%. Apple's SG&A was $30.74M, missing the average forecast of $33.99M by -9.55%. Lastly, the company's EPS was $-12.42, missing the average prediction of $-1.267K by -99.02%. In terms of the last quarterly report (Jun 2023), T2 Biosystems's revenue was $1.96M, missing the average analysts' forecast of $2.17M by -9.49%. The company's EBITDA was $-13.051M, beating the average prediction of $-2.17M by 501.43%. T2 Biosystems's net income was $-6.347M, missing the average estimation of $-376M by -98.31%. The company's SG&A was $6.3M, beating the average forecast of $4.47M by 40.89%. Lastly, the company's EPS was $-7.84, missing the average prediction of $-26.667 by -70.60%